Literature DB >> 10901370

Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma.

G H Shen1, M Ghazizadeh, O Kawanami, H Shimizu, E Jin, T Araki, Y Sugisaki.   

Abstract

The influence of vascular endothelial growth factor (VEGF) expression and microvessel density (MVD) on prognosis and the relationship between VEGF expression and MVD in ovarian carcinoma are not well defined. We studied VEGF expression in parallel with MVD by immunohistochemistry in 94 ovarian tumours (64 malignant, 13 borderline, and 17 benign) and correlated the results with the clinicopathologic prognostic factors of the disease to clarify their significance in this disease. Assessment of VEGF mRNA isoforms by RT-PCR was also performed. Of the malignant, borderline, and benign ovarian tumours respectively, two (3%), four (31%) and 16 (94%) were negative, 31 (48%), seven (54%) and one (6%) had low expressions, and 31 (48%), two (15%) and none (0%) had high expressions of VEGF. There were significant associations between the VEGF expression and disease stage (P= 0.002), histologic grade (P= 0.0004), and patient outcome (P= 0.0002). MVD did not correlate significantly with the clinicopathologic parameters. Likewise, no correlation was found between MVD and VEGF expression. The survival of patients with high VEGF expression was significantly worse than that of patients with low and negative VEGF expression (P = 0.0004). Multivariate analysis revealed that disease stage and VEGF expression were significant and independent prognostic indicators of overall survival time (P = 0.008 and P = 0.006 respectively). These findings suggest that in conjunction with the established clinicopathologic prognostic parameters of ovarian carcinoma, VEGF expression may enhance the predictability of patients at high risk for tumour progression who are potential candidates for further aggressive therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10901370      PMCID: PMC2363477          DOI: 10.1054/bjoc.2000.1228

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  31 in total

1.  What is the evidence that tumors are angiogenesis dependent?

Authors:  J Folkman
Journal:  J Natl Cancer Inst       Date:  1990-01-03       Impact factor: 13.506

Review 2.  How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial Award lecture.

Authors:  J Folkman
Journal:  Cancer Res       Date:  1986-02       Impact factor: 12.701

3.  Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells.

Authors:  N Ferrara; W J Henzel
Journal:  Biochem Biophys Res Commun       Date:  1989-06-15       Impact factor: 3.575

4.  Vascular permeability factor, an endothelial cell mitogen related to PDGF.

Authors:  P J Keck; S D Hauser; G Krivi; K Sanzo; T Warren; J Feder; D T Connolly
Journal:  Science       Date:  1989-12-08       Impact factor: 47.728

5.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma.

Authors:  N Weidner; J P Semple; W R Welch; J Folkman
Journal:  N Engl J Med       Date:  1991-01-03       Impact factor: 91.245

6.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo.

Authors:  K J Kim; B Li; J Winer; M Armanini; N Gillett; H S Phillips; N Ferrara
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

7.  Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant.

Authors:  B Millauer; L K Shawver; K H Plate; W Risau; A Ullrich
Journal:  Nature       Date:  1994-02-10       Impact factor: 49.962

8.  Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.

Authors:  D R Senger; S J Galli; A M Dvorak; C A Perruzzi; V S Harvey; H F Dvorak
Journal:  Science       Date:  1983-02-25       Impact factor: 47.728

9.  Vascular permeability factor gene expression in normal and neoplastic human ovaries.

Authors:  T A Olson; D Mohanraj; L F Carson; S Ramakrishnan
Journal:  Cancer Res       Date:  1994-01-01       Impact factor: 12.701

10.  The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor.

Authors:  C de Vries; J A Escobedo; H Ueno; K Houck; N Ferrara; L T Williams
Journal:  Science       Date:  1992-02-21       Impact factor: 47.728

View more
  53 in total

1.  Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma.

Authors:  Lin Zhang; Nuo Yang; Jose-Ramon Conejo Garcia; Alisha Mohamed; Fabian Benencia; Stephen C Rubin; David Allman; George Coukos
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

2.  Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer.

Authors:  Setsuko K Chambers; Mary C Clouser; Amanda F Baker; Denise J Roe; Haiyan Cui; Molly A Brewer; Kenneth D Hatch; Michael S Gordon; Mike F Janicek; Jeffrey D Isaacs; Alan N Gordon; Raymond B Nagle; Heather M Wright; Janice L Cohen; David S Alberts
Journal:  Clin Cancer Res       Date:  2010-11-01       Impact factor: 12.531

3.  Preoperative platelet/lymphocyte ratio is a superior prognostic factor compared to other systemic inflammatory response markers in ovarian cancer patients.

Authors:  Wei-wei Zhang; Ke-jun Liu; Guo-lin Hu; Wei-jiang Liang
Journal:  Tumour Biol       Date:  2015-06-11

4.  Vascular endothelial growth factor (VEGF) polymorphism and increased risk of epithelial ovarian cancer.

Authors:  José Augusto Rinck-Junior; Cristiane Oliveira; Gustavo Jacob Lourenço; Regina Aparecida Martinho Sagarra; Sophie Françoise Mauricette Derchain; José Getulio Segalla; Carmen Silvia Passos Lima
Journal:  J Cancer Res Clin Oncol       Date:  2014-08-05       Impact factor: 4.553

Review 5.  Angiogenesis and ovarian cancer.

Authors:  César Gómez-Raposo; Marta Mendiola; Jorge Barriuso; Enrique Casado; David Hardisson; Andrés Redondo
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

6.  Bevacizumab and ovarian cancer.

Authors:  Agustin Garcia; Harpreet Singh
Journal:  Ther Adv Med Oncol       Date:  2013-03       Impact factor: 8.168

Review 7.  Antiangiogenic drugs in ovarian cancer.

Authors:  G C Kumaran; G C Jayson; A R Clamp
Journal:  Br J Cancer       Date:  2008-11-11       Impact factor: 7.640

8.  Inhibition of epidermoid carcinoma A431 cell growth and angiogenesis in nude mice by early and late treatment with a novel dextran derivative.

Authors:  M Di Benedetto; A Starzec; R Vassy; G Y Perret; M Crépin; M Kraemer
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

9.  Antivascular therapy for epithelial ovarian cancer.

Authors:  Francois P Duhoux; Jean-Pascal Machiels
Journal:  J Oncol       Date:  2009-12-23       Impact factor: 4.375

10.  A current review of targeted therapeutics for ovarian cancer.

Authors:  Susana M Campos; Sue Ghosh
Journal:  J Oncol       Date:  2010-01-03       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.